Tevogen leverages Microsoft partnership to deliver target identification for HPV

Tevogen Bio (TVGN) announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (MSFT) (MSFR) Using Microsoft’s suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen’s proprietary ExacTcell technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.